Int J Stomatol

Inter J Stomatol ›› 2018, Vol. 45 ›› Issue (6): 703-709.doi: 10.7518/gjkq.2018.06.014

• Reviews • Previous Articles     Next Articles

Research progress on the relationship between periodontitis and sclerostin

Caiwei Xu,Yi Xue(),Zhongyin Wu   

  1. Dept. of Stomatology, Bethune International Peace Hospital, Shijiazhuang 050000, China
  • Received:2017-11-04 Revised:2018-06-16 Online:2018-11-01 Published:2018-11-15
  • Contact: Yi Xue E-mail:dentvip@qq.com
  • Supported by:
    This study was supported by The 2017 Heibei Provincial Government Foundation for Medical Talent Training and Fundamental Research(2017-46)

RichHTML

10

PDF (PC)

800

Abstract:

Alveolar bone resorption is one of the main pathological changes brought about by periodontitis. Sclerostin is characterized by suppressing bone formation. Sclerostin antibody could promote bone formation. Sclerostin is involved in the occurrence and progression of periodontitis. This paper reviews the progress of research on the relationship between sclerostin and periodontitis.

Key words: periodontitis, sclerostin, Wnt signaling pathway

CLC Number: 

  • R781.4 +2

TrendMD: 
[1] Brunkow ME, Gardner JC, Van Ness J , et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein[J]. Am J Hum Genet, 2001,68(3):577-589.
doi: 10.1086/318811 pmid: 11179006
[2] Moester MJ, Papapoulos SE, Löwik CW , et al. Scle-rostin: current knowledge and future perspectives[J]. Calcif Tissue Int, 2010,87(2):99-107.
doi: 10.1007/s00223-010-9372-1
[3] van Lierop AH, Hamdy NA, van Egmond ME , et al. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers[J]. J Bone Miner Res, 2013,28(4):848-854.
doi: 10.1002/jbmr.1794 pmid: 23074140
[4] Gregson CL, Poole KE , McCloskey EV, et al. Eleva-ted circulating sclerostin concentrations in indivi-duals with high bone mass, with and without LRP5 mutations[J]. J Clin Endocrinol Metab, 2014,99(8):2897-2907.
doi: 10.1210/jc.2013-3958 pmid: 24606091
[5] Hay E, Bouaziz W, Funck-Brentano T , et al. Scle-rostin and bone aging: a mini-review[J]. Geronto-logy, 2016,62(6):618-623.
doi: 10.1159/000446278 pmid: 27177738
[6] Lewiecki EM . Sclerostin: a novel target for interven-tion in the treatment of osteoporosis[J]. Discov Med, 2011,12(65):263-273.
[7] Sharifi M, Ereifej L, Lewiecki EM . Sclerostin and skeletal health[J]. Rev Endocr Metab Disord, 2015,16(2):149-156.
doi: 10.1007/s11154-015-9311-6
[8] Winkler DG, Yu CP, Geoghegan JC , et al. Noggin and sclerostin bone morphogenetic protein anta-gonists form a mutually inhibitory complex[J]. J Biol Chem, 2004,279(35):36293-36298.
doi: 10.1074/jbc.M400521200 pmid: 15199066
[9] van Bezooijen RL, Roelen BA, Visser A , et al. Scle-rostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist[J]. J Exp Med, 2004,199(6):805-814.
doi: 10.1084/jem.20031454
[10] Yavropoulou MP, Yovos JG . The role of the Wnt signaling pathway in osteoblast commitment and differentiation[J]. Hormones (Athens), 2007,6(4):279-294.
doi: 10.14310/horm.2002.1111024 pmid: 18055419
[11] Graham JM, Ayati BP, Holstein SA , et al. The role of osteocytes in targeted bone remodeling: a mathe-matical model[J]. PLoS One, 2013,8(5):e63884.
doi: 10.1371/journal.pone.0063884 pmid: 23717504
[12] Tonna S, Sims NA . Talking among ourselves: para-crine control of bone formation within the osteoblast lineage[J]. Calcif Tissue Int, 2014,94(1):35-45.
doi: 10.1007/s00223-013-9738-2 pmid: 23695526
[13] Becker CB . Sclerostin inhibition for osteoporosis—a new approach[J]. N Engl J Med, 2014,370(5):476-477.
doi: 10.1056/NEJMe1315500 pmid: 24382003
[14] Sarahrudi K, Thomas A, Albrecht C , et al. Strongly enhanced levels of sclerostin during human fracture healing[J]. J Orthop Res, 2012,30(10):1549-1555.
doi: 10.1002/jor.v30.10
[15] Glass DA, Bialek P, Ahn JD , et al. Canonical Wnt signaling in differentiated osteoblasts controls osteo-clast differentiation[J]. Dev Cell, 2005,8(5):751-764.
doi: 10.1016/j.devcel.2005.02.017 pmid: 15866165
[16] Glass DA, Karsenty G . Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation[J]. Ann N Y Acad Sci, 2006,1068:117-130.
doi: 10.1196/annals.1346.015 pmid: 16831912
[17] Baron R, Hesse E . Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives[J]. J Clin Endocrinol Metab, 2012,97(2):311-325.
doi: 10.1210/jc.2011-2332 pmid: 22238383
[18] Canalis E, Giustina A, Bilezikian JP . Mechanisms of anabolic therapies for osteoporosis[J]. N Engl J Med, 2007,357(9):905-916.
doi: 10.1056/NEJMra067395 pmid: 17761594
[19] Evenepoel P , D’Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease[J]. Kidney Int, 2015,88(2):235-240.
doi: 10.1038/ki.2015.156 pmid: 26083653
[20] Burgers TA, Williams BO . Regulation of Wnt/β- catenin signaling within and from osteocytes[J]. Bone, 2013,54(2):244-249.
doi: 10.1016/j.bone.2013.02.022 pmid: 3652284
[21] Dallas SL, Prideaux M, Bonewald LF . The osteocyte: an endocrine cell . . and more[J]. Endocr Rev, 2013,34(5):658-690.
doi: 10.1210/er.2012-1026 pmid: 23612223
[22] Mattoo RL . The roles of fibroblast growth factor (FGF)-23, α-klotho and furin protease in calcium and phosphate homeostasis: a mini-review[J]. Indian J Clin Biochem, 2014,29(1):8-12.
doi: 10.1007/s12291-013-0324-1 pmid: 24478543
[23] Seifert ME, de las Fuentes L, Rothstein M , et al. Ef-fects of phosphate binder therapy on vascular stif-fness in early-stage chronic kidney disease[J]. Am J Nephrol, 2013,38(2):158-167.
doi: 10.1159/000353569 pmid: 3874122
[24] Lin CW, Jiang X, Dai ZQ , et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling[J]. J Bone Miner Res, 2009,24(10):1651-1661.
doi: 10.1359/jbmr.090411
[25] Kramer I, Loots GG, Studer A , et al. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice[J]. J Bone Miner Res, 2010,25(2):178-189.
doi: 10.1359/jbmr.090730 pmid: 3153379
[26] Ominsky MS, Vlasseros F, Jolette J , et al. Two doses of sclerostin antibody in cynomolgus monkeys in-creases bone formation, bone mineral density, and bone strength[J]. J Bone Miner Res, 2010,25(5):948-959.
doi: 10.1002/jbmr.14
[27] Padhi D, Jang G, Stouch B , et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody[J]. J Bone Miner Res, 2011,26(1):19-26.
doi: 10.1002/jbmr.173 pmid: 20593411
[28] Li XD, Ominsky MS, Warmington KS , et al. Sclero-stin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of pos-tmenopausal osteoporosis[J]. J Bone Miner Res, 2009,24(4):578-588.
doi: 10.1359/jbmr.081206 pmid: 19049336
[29] Tian XY, Setterberg RB, Li XD , et al. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow com-position in adult female rats[J]. Bone, 2010,47(3):529-533.
doi: 10.1016/j.bone.2010.05.032 pmid: 20561907
[30] Gori F, Hofbauer LC, Dunstan CR , et al. The expre-ssion of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated[J]. Endo-crinology, 2000,141(12):4768-4776.
[31] Wijenayaka AR, Kogawa M, Lim HP , et al. Scle-rostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway[J]. PLoS One, 2011,6(10):e25900.
doi: 10.1371/journal.pone.0025900
[32] Appelman-Dijkstra NM, Papapoulos SE . Sclerostin inhibition in the management of osteoporosis[J]. Calcif Tissue Int, 2016,98(4):370-380.
doi: 10.1007/s00223-016-0126-6 pmid: 23325222
[33] Kogawa M, Wijenayaka AR, Ormsby RT , et al. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2[J]. J Bone Miner Res, 2013,28(12):2436-2448.
doi: 10.1002/jbmr.2003 pmid: 23737439
[34] Napimoga MH , Nametala C, da Silva FL, et al. In-volvement of the Wnt-β-catenin signalling anta-gonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis[J]. J Clin Periodontol, 2014,41(6):550-557.
doi: 10.1111/jcpe.12245
[35] Lehnen SD, Götz W, Baxmann M , et al. Immunohis-tochemical evidence for sclerostin during cemento-genesis in mice[J]. Ann Anat, 2012,194(5):415-421.
doi: 10.1016/j.aanat.2012.02.014 pmid: 22560000
[36] Jäger A, Götz W, Lossdörfer S , et al. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro[J]. J Periodont Res, 2010,45(2):246-254.
doi: 10.1111/j.1600-0765.2009.01227.x pmid: 19778325
[37] 林婷婷, 陆尔奕 . SOST基因在人牙周膜细胞矿化诱导过程中的表达[J]. 上海口腔医学, 2012,21(2):139-144.
Lin TT, Lu EY . Effect of induced-mineralization on the expression of SOST in human periodontal liga-ment cells[J]. Shanghai J Stomatol, 2012,21(2):139-144.
[38] Kim JH, Lee DE, Cha JH , et al. Receptor activator of nuclear factor-κB ligand and sclerostin expression in osteocytes of alveolar bone in rats with ligature-induced periodontitis[J]. J Periodontol, 2014,85(11):e370-e378.
doi: 10.1902/jop.2014.140230 pmid: 25070541
[39] Kim JH, Lee DE, Woo GH , et al. Osteocytic sclero-stin expression in alveolar bone in rats with diabetes mellitus and ligature-induced periodontitis[J]. J Periodontol, 2015,86(8):1005-1011.
doi: 10.1902/jop.2015.150083 pmid: 25855571
[40] Veverka V, Henry AJ, Slocombe PM , et al. Charac-terization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation[J]. J Biol Chem, 2009,284(16):10890-10900.
doi: 10.1074/jbc.M807994200
[41] Poole KE, van Bezooijen RL, Loveridge N , et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation[J]. FASEB J, 2005,19(13):1842-1844.
doi: 10.1096/fj.05-4221fje pmid: 16123173
[42] Silvestrini G, Ballanti P, Leopizzi M , et al. Effects of intermittent parathyroid hormone (PTH) adminis-tration on SOST mRNA and protein in rat bone[J]. J Mol Histol, 2007,38(4):261-269.
doi: 10.1007/s10735-007-9096-3 pmid: 17549589
[43] Rooker SM, Liu B, Helms JA . Role of Wnt signaling in the biology of the periodontium[J]. Dev Dyn, 2010,239(1):140-147.
doi: 10.1002/dvdy.22003 pmid: 3280952
[44] Balli U, Aydogdu A, Dede FO , et al. Gingival cre-vicular fluid levels of sclerostin, osteoprotegerin, and receptor activator of nuclear factor-κB ligand in perio-dontitis[J]. J Periodontol, 2015,86(12):1396-1404.
doi: 10.1902/jop.2015.150270 pmid: 26367496
[45] Kim BJ, Bae SJ, Lee SY , et al. TNF-α mediates the stimulation of sclerostin expression in an estrogen-deficient condition[J]. Biochem Biophys Res Commun, 2012,424(1):170-175.
doi: 10.1016/j.bbrc.2012.06.100 pmid: 22735261
[46] Cenci S, Weitzmann MN, Roggia C , et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α[J]. J Clin Invest, 2000,106(10):1229-1237.
doi: 10.1172/JCI11066 pmid: 11086024
[47] Ryan MR, Shepherd R, Leavey JK , et al. An IL-7-dependent rebound in thymic T cell output contri-butes to the bone loss induced by estrogen deficiency[J]. Proc Natl Acad Sci USA, 2005,102(46):16735-16740.
doi: 10.1073/pnas.0505168102 pmid: 16267136
[48] Baek K, Hwang HR, Park HJ , et al. TNF-α upregu-lates sclerostin expression in obese mice fed a high-fat diet[J]. J Cell Physiol, 2014,229(5):640-650.
doi: 10.1002/jcp.24487
[49] Klein-Nulend J, Bacabac RG, Bakker AD . Mecha-nical loading and how it affects bone cells: the role of the osteocyte cytoskeleton in maintaining our skeleton[J]. Eur Cell Mater, 2012,24:278-291.
doi: 10.1101/cshperspect.a007435 pmid: 23007912
[50] Klein-Nulend J, Bakker AD, Bacabac RG , et al. Me-chanosensation and transduction in osteocytes[J]. Bone, 2013,54(2):182-190.
doi: 10.1138/20060233 pmid: 1847717
[51] Spatz JM, Fields EE, Yu EW , et al. Serum sclerostin increases in healthy adult men during bed rest[J]. J Clin Endocrinol Metab, 2012,97(9):E1736-E1740.
doi: 10.1210/jc.2012-1579 pmid: 22767636
[52] Frings-Meuthen P, Boehme G, Liphardt AM , et al. Sclerostin and DKK1 levels during 14 and 21 days of bed rest in healthy young men[J]. J Musculoskelet Neuronal Interact, 2013,13(1):45-52.
doi: 10.1016/j.ijpsycho.2013.03.009 pmid: 23445914
[53] Ominsky MS, Li CY, Li XD , et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones[J]. J Bone Miner Res, 2011,26(5):1012-1021.
doi: 10.1002/jbmr.307 pmid: 21542004
[54] Li CY, Ominsky MS, Tan HL , et al. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene[J]. Bone, 2011,49(6):1178-1185.
doi: 10.1016/j.bone.2011.08.012 pmid: 21890008
[55] Taut AD, Jin QM, Chung JH , et al. Sclerostin anti-body stimulates bone regeneration after experimental periodontitis[J]. J Bone Miner Res, 2013,28(11):2347-2356.
doi: 10.1002/jbmr.1984 pmid: 23712325
[56] Kuchler U, Schwarze UY, Dobsak T , et al. Dental and periodontal phenotype in sclerostin knockout mice[J]. Int J Oral Sci, 2014,6(2):70-76.
doi: 10.1038/ijos.2014.12 pmid: 24699186
[57] Chen H, Xu XC, Liu M , et al. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of loca-lized periodontitis[J]. Bone, 2015,76:141-148.
doi: 10.1016/j.bone.2015.04.002 pmid: 25868799
[58] Ren YS, Han XL, Ho SP , et al. Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model[J]. FASEB J, 2015,29(7):2702-2711.
doi: 10.1096/fj.14-265496
[59] Roguljic H, Matthews BG, Yang W , et al. In vivo identification of periodontal progenitor cells[J]. J Dent Res, 2013,92(8):709-715.
doi: 10.1177/0022034513493434 pmid: 23735585
[60] Rios HF, Ma D, Xie Y , et al. Periostin is essential for the integrity and function of the periodontal ligament during occlusal loading in mice[J]. J Perio-dontol, 2008,79(8):1480-1490.
doi: 10.1902/jop.2008.070624 pmid: 2581516
[1] Fu Yu, He Wei, Huang Lan. Ferroptosis and its implication in oral diseases [J]. Int J Stomatol, 2024, 51(1): 36-44.
[2] Luo Xiaojie,Wang Dexu,Chen Xiaotao. Relationship between periodontitis and ferroptosis based on bioinformatics analysis [J]. Int J Stomatol, 2023, 50(6): 661-668.
[3] Huang Yuanhong,Peng Xian,Zhou Xuedong.. Progress in research into the effect of Rhizoma Drynariae on the treatment of bone-related diseases in the oral cavity [J]. Int J Stomatol, 2023, 50(6): 679-685.
[4] Hu Jia,Wang Xiuqing,Lu Guoying,Huang Xiaojing.. Regenerative endodontic procedures for permanent tooth with immature apices in adult patients [J]. Int J Stomatol, 2023, 50(6): 686-695.
[5] Gong Meiling,Cheng Xingqun,Wu Hongkun.. Research progress on the correlation between Parkinson’s disease and periodontitis [J]. Int J Stomatol, 2023, 50(5): 587-593.
[6] Xu Zhibo,Meng Xiuping.. Research progress on mechanism of Enterococcus faecalis escaping host immune defense [J]. Int J Stomatol, 2023, 50(5): 613-617.
[7] Sun Jia,Han Ye,Hou Jianxia. Research progress on the role of interleukin-6-hepcidin signal axis in regulating the pathogenesis of periodontitis-associated anemia [J]. Int J Stomatol, 2023, 50(3): 329-334.
[8] Liang Zhiying,Zhao Yuanxi,Zhu Jiani,Su Qin.. Retrospective analysis of clinical data of 288 cases of endodontic microsurgery on anterior teeth [J]. Int J Stomatol, 2023, 50(2): 166-171.
[9] Liu Tiqian,Liang Xing,Liu Weiqing,Li Xiaohong,Zhu Rui.. Research progress on the role and mechanism of occlusal trauma in the development of periodontitis [J]. Int J Stomatol, 2023, 50(1): 19-24.
[10] Li Qiong,Yu Weixian. Research progress on resveratrol for the treatment of periodontitis and its bioavailability [J]. Int J Stomatol, 2023, 50(1): 25-31.
[11] Huang Weikun,Xu Qiuyan,Zhou Ting.. Role of baicalin and mechanisms through which baicalin attenuates oxidative stress injury induced by lipopolysaccharide on macrophages [J]. Int J Stomatol, 2022, 49(5): 521-528.
[12] Zhou Jianpeng,Xie Xudong,Zhao Lei,Wang Jun.. Research progress on the roles and mechanisms of T-helper 17 cells and interleukin-17 in periodontitis [J]. Int J Stomatol, 2022, 49(5): 586-592.
[13] Chen Huiyu,Bai Mingru,Ye Ling.. Progress in understanding the correlations between semaphorin 3A and common oral diseases [J]. Int J Stomatol, 2022, 49(5): 593-599.
[14] Zhou Jiajia,Zhao Lei,Xu Xin. Research progress on the genetic polymorphism of periodontitis [J]. Int J Stomatol, 2022, 49(4): 432-440.
[15] Zhu Jiani,Su Qin. Research status of the use of root canal and periapical microflora in refractory periapical periodontitis [J]. Int J Stomatol, 2022, 49(3): 283-289.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[7] . [J]. Foreign Med Sci: Stomatol, 2005, 32(06): 458 -460 .
[8] . [J]. Foreign Med Sci: Stomatol, 2005, 32(06): 452 -454 .
[9] . [J]. Inter J Stomatol, 2008, 35(S1): .
[10] . [J]. Inter J Stomatol, 2008, 35(S1): .